Robust humoral and cellular immune responses and low risk for reinfection at least 8 months following asymptomatic to mild COVID-19

↓ Direkt till sidans innehåll
↓ Direkt till sidans sekundära innehåll (sidomenyn)

Sökning: WFRF:(Gabrielsson Sara) > (2020-2023) > Robust humoral and ...

Robust humoral and cellular immune responses and low risk for reinfection at least 8 months following asymptomatic to mild COVID-19

Havervall, Sebastian (författare): Karolinska Institutet

Ng, Henry (författare): Uppsala universitet,Integrativ Fysiologi,Department of Clinical Sciences, Karolinska Institutet Danderyd Hospital, Stockholm, Sweden

Jernbom Falk, August (författare): KTH,Affinitets-proteomik,Science for Life Laboratory, SciLifeLab,Department of Protein Science, SciLifeLab, KTH Royal Institute of Technology, Stockholm, Sweden

visa fler...

Greilert-Norin, Nina (författare): Department of Clinical Sciences, Karolinska Institutet Danderyd Hospital, Stockholm, Sweden

Månberg, Anna, 1985- (författare): KTH,Science for Life Laboratory, SciLifeLab,Affinitets-proteomik,Department of Protein Science, SciLifeLab, KTH Royal Institute of Technology, Stockholm, Sweden

Marking, Ulrika (författare): Karolinska Institutet

Laurén, Ida (författare): Uppsala universitet,Institutionen för farmaci

Gabrielsson, Lena (författare): Department of Clinical Sciences, Karolinska Institutet Danderyd Hospital, Stockholm, Sweden

Salomonsson, Ann-Christin (författare): Department of Clinical Sciences, Karolinska Institutet Danderyd Hospital, Stockholm, Sweden

Aguilera, Katherina (författare): Department of Clinical Sciences, Karolinska Institutet Danderyd Hospital, Stockholm, Sweden

Kihlgren, Martha (författare): Department of Clinical Sciences, Karolinska Institutet Danderyd Hospital, Stockholm, Sweden

Månsson, Maja (författare): Department of Clinical Sciences, Karolinska Institutet Danderyd Hospital, Stockholm, Sweden

Rosell, Axel (författare): Karolinska Institutet

Hellström, Cecilia (författare): KTH,Affinitets-proteomik,Science for Life Laboratory, SciLifeLab,Department of Protein Science, SciLifeLab, KTH Royal Institute of Technology, Stockholm, Sweden

Andersson, Eni (författare): KTH,Science for Life Laboratory, SciLifeLab,Affinitets-proteomik,Department of Protein Science, SciLifeLab, KTH Royal Institute of Technology, Stockholm, Sweden

Olofsson, Jennie (författare): KTH,Science for Life Laboratory, SciLifeLab,Affinitets-proteomik,Department of Protein Science, SciLifeLab, KTH Royal Institute of Technology, Stockholm, Sweden

Skoglund, Lovisa (författare): Department of Protein Science, SciLifeLab, KTH Royal Institute of Technology, Stockholm, Sweden

Yousef, Jamil (författare): Department of Protein Science, SciLifeLab, KTH Royal Institute of Technology, Stockholm, Sweden

Pin, Elisa (författare): KTH,Affinitets-proteomik,Science for Life Laboratory, SciLifeLab,Department of Protein Science, SciLifeLab, KTH Royal Institute of Technology, Stockholm, Sweden

Lord, Martin (författare): Uppsala universitet,Institutionen för farmaci

Åberg, Mikael (författare): Uppsala universitet,Science for Life Laboratory, SciLifeLab,Klinisk kemi

Hedhammar, My, Professor, 1975- (författare): KTH,Proteinteknologi,Science for Life Laboratory, SciLifeLab,Department of Protein Science, SciLifeLab, KTH Royal Institute of Technology, Stockholm, Sweden

Tegel, Hanna (författare): KTH,Proteinvetenskap,Science for Life Laboratory, SciLifeLab,Department of Protein Science, SciLifeLab, KTH Royal Institute of Technology, Stockholm, Sweden

Dönnes, Pierre (författare): SciCross AB, Skövde, Sweden

Phillipson, Mia, 1973- (författare): Uppsala universitet,Integrativ Fysiologi

Nilsson, Peter (författare): KTH,Science for Life Laboratory, SciLifeLab,Affinitets-proteomik,Department of Protein Science, SciLifeLab, KTH Royal Institute of Technology, Stockholm, Sweden

Klingström, Jonas (författare): Karolinska Institutet

Mangsbo, Sara, 1981- (författare): Uppsala universitet,Institutionen för farmaci

Hober, Sophia, Professor, 1965- (författare): KTH,Science for Life Laboratory, SciLifeLab,Proteinteknologi,Department of Protein Science, SciLifeLab, KTH Royal Institute of Technology, Stockholm, Sweden

Thålin, Charlotte (författare): Karolinska Institutet

visa färre...

(creator_code:org_t)

2021-09-27
2022
Engelska.
Ingår i: Journal of Internal Medicine. - : John Wiley & Sons. - 0954-6820 .- 1365-2796. ; 291:1, s. 72-80

Relaterad länk:: https://doi.org/10.1...; visa fler...; https://uu.diva-port... (primary) (Raw object); https://www.ncbi.nlm...; https://urn.kb.se/re...; https://doi.org/10.1...; https://urn.kb.se/re...; http://kipublication...; visa färre...

Tidskriftsartikel (refereegranskat)

Abstract Ämnesord

Stäng

Background: Emerging data support detectable immune responses for months after severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and vaccination, but it is not yet established to what degree and for how long protection against reinfection lasts.Methods: We investigated SARS-CoV-2-specific humoral and cellular immune responses more than 8 months post-asymptomatic, mild and severe infection in a cohort of 1884 healthcare workers (HCW) and 51 hospitalized COVID-19 patients. Possible protection against SARS-CoV-2 reinfection was analyzed by a weekly 3-month polymerase chain reaction (PCR) screening of 252 HCW that had seroconverted 7 months prior to start of screening and 48 HCW that had remained seronegative at multiple time points.Results: All COVID-19 patients and 96% (355/370) of HCW who were anti-spike IgG positive at inclusion remained anti-spike IgG positive at the 8-month follow-up. Circulating SARS-CoV-2-specific memory T cell responses were detected in 88% (45/51) of COVID-19 patients and in 63% (233/370) of seropositive HCW. The cumulative incidence of PCR-confirmed SARS-CoV-2 infection was 1% (3/252) among anti-spike IgG positive HCW (0.13 cases per 100 weeks at risk) compared to 23% (11/48) among anti-spike IgG negative HCW (2.78 cases per 100 weeks at risk), resulting in a protective effect of 95.2% (95% CI 81.9%-99.1%).Conclusions: The vast majority of anti-spike IgG positive individuals remain anti-spike IgG positive for at least 8 months regardless of initial COVID-19 disease severity. The presence of anti-spike IgG antibodies is associated with a substantially reduced risk of reinfection up to 9 months following asymptomatic to mild COVID-19.

Ämnesord

MEDICIN OCH HÄLSOVETENSKAP -- Klinisk medicin -- Infektionsmedicin (hsv//swe)
MEDICAL AND HEALTH SCIENCES -- Clinical Medicine -- Infectious Medicine (hsv//eng)
MEDICIN OCH HÄLSOVETENSKAP -- Medicinska och farmaceutiska grundvetenskaper -- Immunologi inom det medicinska området (hsv//swe)
MEDICAL AND HEALTH SCIENCES -- Basic Medicine -- Immunology in the medical area (hsv//eng)

Nyckelord

COVID-19
SARS-CoV-2
humoral response
long-term immunity
reinfection
Biotechnology

Publikations- och innehållstyp

ref (ämneskategori)
art (ämneskategori)

Hitta via bibliotek

Journal of Internal Medicine (Sök värdpublikationen i LIBRIS)

Till lärosätets databas

Hitta mer i SwePub

Om ämnet

MEDICIN OCH HÄLSOVETENSKAP: MEDICIN OCH HÄLS ...; och Klinisk medicin; och Infektionsmedici ...

MEDICIN OCH HÄLSOVETENSKAP: MEDICIN OCH HÄLS ...; och Medicinska och f ...; och Immunologi inom ...

Artiklar i publikationen: Journal of Inter ...

Av lärosätet: Uppsala universitet; Kungliga Tekniska Högskolan; Karolinska Institutet

Sök utanför SwePub

Sök vidare i:: Google; Google Book Search; Google Scholar

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

LIBRIS.kb.se